149400-88-4 Usage
General Description
4-amidinoindan-1-one 2'-amidinohydrazone is a chemical compound that is a potent and selective inhibitor of factor Xa, an enzyme involved in blood coagulation. It has been studied for its potential use as an anticoagulant and antithrombotic agent, and has shown promising results in preclinical studies. 4-amidinoindan-1-one 2'-amidinohydrazone has also been investigated for its potential use in the treatment of thrombotic disorders, such as deep vein thrombosis and pulmonary embolism. It works by binding to factor Xa and inhibiting its activity, which prevents the formation of blood clots. Further research is needed to determine its safety and efficacy for clinical use, but 4-amidinoindan-1-one 2'-amidinohydrazone holds potential as a valuable therapeutic agent for the prevention and treatment of thrombotic conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 149400-88-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,4,9,4,0 and 0 respectively; the second part has 2 digits, 8 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 149400-88:
(8*1)+(7*4)+(6*9)+(5*4)+(4*0)+(3*0)+(2*8)+(1*8)=134
134 % 10 = 4
So 149400-88-4 is a valid CAS Registry Number.
149400-88-4Relevant articles and documents
4-Amidinoindan-1-one 2'-amidinohydrazone: A new potent and selective inhibitor of S-adenosylmethionine decarboxylase
Stanek,Caravatti,Frei,Furet,Mett,Schneider,Regenass
, p. 2168 - 2171 (1993)
Two isomeric amidino-2-acetylpyridine amidinohydrazones, 11 and 12, and 4- amidinoindanone amidinohydrazone, 17, have been synthesized and tested for inhibition of S-adenosylmethionine decarboxylase (SAMDC) and diamine oxidase and for antiproliferative activity against T24 human bladder carcinoma cells. Compound 11 inhibited SAMDC with an IC50 of 10 nM and was 140- and >500- fold more potent than methylglyoxal bis(guanylhydrazone) (MGBG) and 12, respectively. The difference in potency between 11 and 12 was interpreted with the help of molecular modeling and appeared to be associated with two different low-energy conformations of the compounds. Compound 17 which represents a conformationally constrained analogue of 11, was superior to the latter and MGBG with respect to selective inhibition of SAMDC and antiproliferative activity, and is of interest as a potential anticancer agent and a drug for the treatment of protozoal and Pneumocystis carinii infections.
